- A set of published rules/criteria that define when tumours in cancer patients improve (respond), stay the same (stabilise) or worsen (progress) during treatments.
- Published in Feb 2000 (updated in 2009) by an international collaboration including
- European Organisation for Research & Treatment of Cancer (EORTC)
- National Cancer Institute of the United States
- National Cancer Institute of Canada Clinical Trials Group
- Today, the majority of clinical trials evaluation cancer treatments for objective response in solid tumours are using RECIST
- Specifically not meant to determine whether patients have improved or not, as these are tumour-centric, not patient centric criteria
- It is not intended that these RECIST guidelines play a role in that decision making, except if determined appropriate by the treating oncologist
- Can be used with CT, MRI or conventional radiography
- Characterise lesions as measurable or non-measurable & target vs non-target
Response Evaluation Criteria In Solid Tumours (RECIST)
02 Tuesday Dec 2014
Posted in Daily reading materials
studyradiologyblog 